China's CanSino Sees Delay In COVID Vaccine Rollout
But Single Shot, Storage Benefits?
The Chinese company is enrolling an additional 10,000-20,000 people in its late-stage coronavirus vaccine study focusing on older and sicker patients.
You may also be interested in...
Special guest, Citeline's Annie Siu, discusses the recent ESMO meeting and Jiangsu Hengrui and BeiGene's PD-1 data for hepatocellular carcinoma in this latest episode of the Chinese-language China Biotech podcast.
China’s Negative List for Foreign Investment explicitly bars “investment and application in human stem cells, genetic diagnosis, and treatment technologies.” But whether that applies to foreign pharma firms developing such modalities in the country remains unclear.
China biotechs appear increasingly interested in partnering with domestic counterparts amid signs the Chinese government's restrictive "COVID Zero" policies are likely to stay until well into 2023.